Current Atherosclerosis Reports

, Volume 12, Issue 6, pp 432–439

Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials

  • Patrick Murray
  • Gary W. Chune
  • Vasudevan A. Raghavan
Article

DOI: 10.1007/s11883-010-0128-1

Cite this article as:
Murray, P., Chune, G.W. & Raghavan, V.A. Curr Atheroscler Rep (2010) 12: 432. doi:10.1007/s11883-010-0128-1

Abstract

The United Kingdom Prospective Diabetes Study (UKPDS) and the Diabetes Chronic Complications Trial (DCCT) are two landmark trials that convincingly demonstrated that tight glycemic control has beneficial effects on microvascular end points. These studies also revealed a “legacy effect,” which is a sustained benefit with respect to cardiovascular disease outcomes seen long after the conclusion of the trial. We discuss possible molecular mechanisms that could play a role in causing the legacy effect.

Keywords

Hyperglycemia Treatment Cardiovascular disease Legacy effect 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Patrick Murray
    • 1
    • 3
  • Gary W. Chune
    • 2
  • Vasudevan A. Raghavan
    • 1
    • 2
    • 4
  1. 1.CardioMetabolic and Lipid Clinic ServicesScott and White/Texas A&M Health Sciences CenterTempleUSA
  2. 2.Division of Endocrinology, Diabetes & MetabolismScott and White/Texas A&M Health Sciences CenterTempleUSA
  3. 3.Department of Pharmacy Practice, Rangel College of PharmacyTexas A&M Health Science CenterTempleUSA
  4. 4.Department of Internal MedicineScott and White/Texas A&M Health Sciences CenterTempleUSA

Personalised recommendations